What is Novelix Pharmaceuticals Ltd (536565) share price return in the past 10 years?

Novelix Pharmaceuticals Ltd share price has appreciated 22.9% annually (CAGR) over the past ten years.

What is the share price of Novelix Pharmaceuticals Ltd (536565)?

Company share prices are keep on changing according to the market conditions. The current trading price of Novelix Pharmaceuticals Ltd (536565) on 04-Jun-2026 16:59:59 at 16:59 is 59.62.

What is the P/E ratio of Novelix Pharmaceuticals?

The latest standalone P/E ratio of Novelix Pharmaceuticals as of 04-Jun-2026 is 55.71.

What is the P/B ratio of Novelix Pharmaceuticals Ltd (536565)?

The latest standalone P/B ratio of Novelix Pharmaceuticals Ltd (536565) as of 04-Jun-2026 is 2.73.

What is the 52-week high and low of Novelix Pharmaceuticals Ltd (536565)?

The 52-week high of Novelix Pharmaceuticals Ltd (536565) is Rs. 70.16 and the 52-week low is Rs. 29.33.

Novelix Pharmaceuticals Ltd (536565) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Novelix Pharmaceuticals Ltd (536565)
Brand: Novelix Pharmaceuticals

Novelix Pharmaceuticals Ltd (536565)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 536565 NSE: Trading | Small Cap | Novelix Pharma Share Price

Novelix Pharmaceuticals Ltd (536565)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 536565 NSE: Trading | Small Cap | Novelix Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹142 Cr.

Current Price

₹59.6

52-Week Low / High

₹29 / 70

TTM EPS

₹1.1

TTM Sales

₹132 Cr.

Book Value per Share

₹21.8

P/E Ratio

55.71

Industry PE

Price to Book (P/B)

2.73

Higher than its 5-year historical median

Price to Sales (P/S)

1.08

Lower than its 5-year historical median

EV/EBITDA

41.02

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.68%

Underperforms industry median

Return on Capital Employed (ROCE)

1.00%

Underperforms industry median

Return on Assets (ROA)

0.49%

Operating Profit Margin

0.5%

Net Profit Margin

0.28%

Gross Profit Margin

0.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

627.96%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

700%

Asset Quality

Promoter Holding

49.43%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹28 Cr.

Equity

₹23.9 Cr.

Face Value

₹10

All Time Low / High

₹1.85 / 74.60

Novelix Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Novelix Pharmaceuticals Ltd a good quality company?

Novelix Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Novelix Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Novelix Pharmaceuticals Ltd vs industry peers?

Novelix Pharmaceuticals Ltd revenue CAGR is 97.20%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Novelix Pharmaceuticals Ltd?

Promoters hold 49.43% of the Novelix Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Novelix Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 21.7% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	1.2%	1.8%	2.5%	1.6%	0.9%	-31.3%	-19.5%	-0.8%	0.3%	1%	-
Value Creation Index ⓘ	-0.9	-0.9	-0.8	-0.9	-0.9	-3.2	-2.4	-1.1	-1.0	-0.9	-
Growth Parameters ⓘ
Sales ⓘ	0.9	3.5	3.1	3.6	1	1	0.8	1.4	4.2	30.7	132
Sales YoY Gr.	-	277.4%	-11.4%	15.4%	-71.3%	-1.9%	-16.8%	66.7%	201.4%	628%	-
Adj EPS ⓘ	0.1	0.1	0.3	0.2	0.1	-4	-0.6	-0.3	-0.1	0.1	1.1
YoY Gr.	-	-22.2%	271.4%	-23.1%	-60%	-5137.5%	NA	NA	NA	NA	-
BVPS (₹) ⓘ	14.1	14.3	14.6	14.8	14.9	10.9	8.9	8.9	9.1	17.6	21.8
Adj Net Profit ⓘ	0.1	0.1	0.2	0.2	0.1	-3.3	-0.5	-0.2	-0.1	0.1	3
Cash Flow from Ops. ⓘ	2	-1.1	1.1	-0.4	1.2	0.6	0.6	-2.4	-0.3	-13.7	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	47.5%	97.2%	231.9%	628%
Adj EPS ⓘ	0%	2.4%	NA	NA
BVPSⓘ	2.5%	3.4%	25.4%	94.2%
Share Price	22.9%	49.8%	79.8%	113.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.6	0.5	1.8	1.3	0.5	-31.3	-6.2	-3.2	-0.7	0.8	5.4
Op. Profit Mgn % ⓘ	42.7	5.2	15.3	5	-27.6	-346.8	-62	-36.9	-5.4	0.5	2.6
Net Profit Mgn % ⓘ	7.5	1.7	6.8	4.4	6.3	-324.1	-58.9	-16.4	-1.2	0.3	1.9
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0.1
Working Cap Days ⓘ	3,301	859	1,033	890	2,851	1,888	1,123	779	345	180	123
Cash Conv. Cycle ⓘ	25	32	85	153	407	87	207	209	94	62	57

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1	4	3	4	1	1	1	1	4	31
Operating Expenses ⓘ +	1	3	3	3	1	5	3	2	4	31
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0
Material Costs	0	3	2	3	1	1	1	1	4	30
Employee Cost	0	0	0	0	0	0	0	0	0	0
Other Costs ⓘ	0	0	0	0	0	3	2	0	0	1
Operating Profit ⓘ	0	0	0	0	-0	-4	-2	-1	-0	0
Operating Profit Margin (%)	42.6%	5.2%	13.9%	5.0%	-27.9%	-348.0%	-242.0%	-36.9%	-5.8%	0.5%
Other Income ⓘ +	0	0	0	0	0	0	1	1	0	0
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	0	0	0
Depreciation ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	0	0	0	0	-3	-2	-0	0	0
Tax ⓘ	0	0	0	-0	0	-0	-0	0	0	0
Profit After Tax	0	0	0	0	0	-3	-2	-0	0	0
PAT Margin (%)	10.6%	4.3%	5.8%	7.0%	9.2%	-324.0%	-185.0%	-4.3%	0.3%	0.3%
Adjusted EPS (₹)	0.1	0.2	0.2	0.3	0.1	-4.0	-1.9	-0.1	0.0	0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Novelix Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	11	12	12	12	12	9	7	7	7	18
Share Capital ⓘ	8	8	8	8	8	8	8	8	8	10
Reserves ⓘ	3	3	4	4	4	1	-1	-1	-1	8
Debt +	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	0	0	0	0	0	0	9
Others Liabilities ⓘ	0	0	0	0	-0	-0	-0	-0	-0	0
Total Liabilities ⓘ	12	12	12	12	12	9	7	7	7	27
Fixed Assets
Net Fixed Assets ⓘ +	1	1	1	0	0	0	0	0	0	0
Gross Block	3	4	4	4	4	4	1	1	1	2
Accumulated Depreciation	3	3	3	3	3	3	1	1	1	1
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	3	2	3	3	4	4	1	3	3	0
Inventories	0	0	0	0	0	0	1	1	1	1
Trade Receivables	0	0	1	2	0	0	0	0	0	18
Cash Equivalents	0	0	0	0	1	2	3	0	0	1
Others Assets ⓘ	8	8	7	7	7	3	3	3	3	7
Total Assets ⓘ	12	12	12	12	12	9	7	7	7	27

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	2	-1	1	-0	1	1	1	-2	-0	-14
PBT ⓘ	0	0	0	0	0	-3	-2	-0	0	0
Adjustment ⓘ	0	0	0	-0	-0	-0	1	-0	-0	0
Changes in Working Capital ⓘ	2	-1	1	-1	2	4	1	-2	-0	-14
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-2	1	-1	0	-0	0	0	0	0	3
Capex	-0	-0	-0	0	-0	-0	-2	-0	0	-0
Net Investments	-2	1	-1	0	-1	0	2	2	-0	3
Others ⓘ	-0	0	0	0	0	0	1	-2	0	0
Cash Flow From Financing Activity ⓘ +	0	0	0	0	0	0	0	0	0	11
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	3
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	8
Net Cash Flow ⓘ	0	-0	-0	0	1	1	1	-2	-0	1

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.86	1.31	1.55	2.1	0.79	-31.32	-19.45	-0.83	0.14	0.68
ROCE (%)	1.2	1.78	2.5	1.6	0.89	-31.33	-19.51	-0.81	0.31	1
Asset Turnover Ratio	0.08	0.3	0.26	0.29	0.09	0.1	0.11	0.2	0.58	1.78
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	24.70	21	88.50	165.20	392.30	29.80	40	37.70	8.80	107.80
Inventory Days	0	22.80	19.40	10.90	32	59.20	168.90	175.70	87.10	12.10
Payable Days	0	0	26.90	27.30	26.60	3.80	0	14.50	2.70	57.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Novelix Pharmaceuticals Ltd FAQs

The current trading price of Novelix Pharma on 04-Jun-2026 16:59 is ₹59.62.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Novelix Pharma stood at ₹142.5 Cr

The latest P/E ratio of Novelix Pharma as of 03-Jun-2026 is 55.71.

The latest P/B ratio of Novelix Pharma as of 03-Jun-2026 is 2.73.

The 52-week high of Novelix Pharma is ₹70.16 and the 52-week low is ₹29.33.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Novelix Pharma is ₹132 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Novelix Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of Novelix Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Novelix Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Novelix Pharmaceuticals Ltd

Trimurthi Drugs & Pharmaceuticals is an India-based company. The Company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The Companyâ€™s range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder. The company since 1976 is built on the philosophy of commitment to quality and responsiveness.

2012 -The Company entered into a Manufacturing Agreement with M/s. Bharat Parenterals Limited, Vadodara, Gujrat for exclusive manufacture of Company's 12 products for export. The Company entered into Distribution Agreement with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam.

Business areas of the company:

The company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products.

Divisions:

Pharma Business, Financial Services, Investment in Shares and Trading in Shares

Novelix Pharmaceuticals Ltd (536565)

Novelix Pharmaceuticals Ltd (536565)

Novelix Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Novelix Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Novelix Pharmaceuticals Ltd FAQs

About Novelix Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Novelix Pharmaceuticals Ltd (536565)

Novelix Pharmaceuticals Ltd (536565)

Novelix Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Novelix Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Novelix Pharmaceuticals Ltd FAQs

What is the share price of Novelix Pharma?

What is the market cap of Novelix Pharma?

What is the P/E ratio of Novelix Pharma?

What is the P/B ratio of Novelix Pharma?

What is the 52-week high and low of Novelix Pharma?

What is the TTM revenue of Novelix Pharma?

Is Novelix Pharmaceuticals Ltd a good quality company?

Is Novelix Pharmaceuticals Ltd undervalued or overvalued?

Is Novelix Pharmaceuticals Ltd a good buy now?

About Novelix Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.